MX2020005932A - Sal de derivado de fenilpropionamida y su metodo de preparacion. - Google Patents
Sal de derivado de fenilpropionamida y su metodo de preparacion.Info
- Publication number
- MX2020005932A MX2020005932A MX2020005932A MX2020005932A MX2020005932A MX 2020005932 A MX2020005932 A MX 2020005932A MX 2020005932 A MX2020005932 A MX 2020005932A MX 2020005932 A MX2020005932 A MX 2020005932A MX 2020005932 A MX2020005932 A MX 2020005932A
- Authority
- MX
- Mexico
- Prior art keywords
- salt
- preparation
- method therefor
- present
- phenylpropionamide
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- DOZZSWAOPDYVLH-UHFFFAOYSA-N 2-phenylpropanamide Chemical class NC(=O)C(C)C1=CC=CC=C1 DOZZSWAOPDYVLH-UHFFFAOYSA-N 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invencion proporciona una sal de un derivado de fenilpropionamida y un metodo de preparacion del mismo; la presente invencion proporciona especificamente un acetato, clorhidrato, fosfato, citrato, benzoato, o fumarato de acido 4-amino-1-((5 2R,5R,8R,14R)-2-(4-aminobutil)-8-bencil-5-isobutil-4 ,7,10-trioxo-14-fenil-3,6,9,12-tetraazapentadecan-1-acil)piperidi n-4-carboxilico y un metodo de preparación del mismo; la sal del compuesto de formula (I) de la presente invencion tiene buena estabilidad y el simple proceso del mismo facilita la sencilla operacion; la invencion se adecua mejor para el tratamiento clinico.(ver fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711272474 | 2017-12-06 | ||
| PCT/CN2018/119309 WO2019109934A1 (zh) | 2017-12-06 | 2018-12-05 | 一种苯基丙酰胺类衍生物的盐及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005932A true MX2020005932A (es) | 2020-08-24 |
Family
ID=66750804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005932A MX2020005932A (es) | 2017-12-06 | 2018-12-05 | Sal de derivado de fenilpropionamida y su metodo de preparacion. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11180530B2 (es) |
| EP (1) | EP3722286B1 (es) |
| JP (1) | JP2021505596A (es) |
| KR (1) | KR20200096588A (es) |
| CN (1) | CN111065631B (es) |
| AU (1) | AU2018380170A1 (es) |
| BR (1) | BR112020011191A2 (es) |
| CA (1) | CA3084201A1 (es) |
| MX (1) | MX2020005932A (es) |
| MY (1) | MY198899A (es) |
| TW (1) | TWI717664B (es) |
| UA (1) | UA126005C2 (es) |
| WO (1) | WO2019109934A1 (es) |
| ZA (1) | ZA202004055B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114615976A (zh) | 2019-08-07 | 2022-06-10 | 人福医药美国公司 | κ阿片受体肽酰胺激动剂 |
| US12616732B2 (en) | 2020-06-25 | 2026-05-05 | Yichang Humanwell Pharmaceuticals Co., Ltd. | Peptides for treatment of medical disorders |
| WO2021262173A1 (en) | 2020-06-25 | 2021-12-30 | Humanwell Pharmaceutical US | Peptides for treatment of medical disorders |
| CN113624898B (zh) * | 2021-08-23 | 2023-08-25 | 成都诺和晟泰生物科技有限公司 | 一种手性镇痛类多肽药物的纯化方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965701A (en) | 1997-12-23 | 1999-10-12 | Ferring Bv | Kappa receptor opioid peptides |
| PL2064228T3 (pl) * | 2006-11-10 | 2013-01-31 | Cara Therapeutics Inc | Syntetyczne amidy peptydowe |
| US7842662B2 (en) | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
| US8906859B2 (en) | 2006-11-10 | 2014-12-09 | Cera Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
| EP2062909A1 (en) * | 2007-11-21 | 2009-05-27 | SOLVAY (Société Anonyme) | Peptide production and purification process |
| WO2010006267A2 (en) * | 2008-07-11 | 2010-01-14 | University Of Kansas | Cyclic tetrapeptides |
| TW201012829A (en) * | 2008-09-22 | 2010-04-01 | Ipsen Mfg Ireland Ltd | Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2 |
| JP6138169B2 (ja) * | 2012-03-05 | 2017-05-31 | ドクター レディズ ラボラトリーズ リミテッド | κオピオイド受容体（ＫＯＲ）アゴニストとしての置換複素環式アセトアミド |
| US20150150935A1 (en) | 2012-06-05 | 2015-06-04 | Cara Therapeutics, Inc. | Peripheral kappa receptor agonists for reducing pain and inflammation |
| WO2014089019A1 (en) | 2012-12-03 | 2014-06-12 | University Of Washington Through Its Center For Commercialization | Methods and compositions for treating vasomotor symptoms |
| WO2014184356A1 (en) | 2013-05-17 | 2014-11-20 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Perhydroquinoxaline derivatives useful as analgesics |
| US20160250277A1 (en) * | 2013-10-28 | 2016-09-01 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting |
| CA2953653C (en) * | 2014-06-26 | 2021-02-16 | Maruishi Pharmaceutical Co., Ltd. | Method for producing synthetic pentapeptide |
| CN114940700A (zh) * | 2016-06-07 | 2022-08-26 | 江苏恒瑞医药股份有限公司 | 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用 |
| JP7028746B2 (ja) | 2018-10-05 | 2022-03-02 | 株式会社日立製作所 | 質問生成装置および質問生成方法 |
-
2018
- 2018-12-05 AU AU2018380170A patent/AU2018380170A1/en not_active Abandoned
- 2018-12-05 MY MYPI2020002491A patent/MY198899A/en unknown
- 2018-12-05 MX MX2020005932A patent/MX2020005932A/es unknown
- 2018-12-05 KR KR1020207019227A patent/KR20200096588A/ko not_active Withdrawn
- 2018-12-05 BR BR112020011191-0A patent/BR112020011191A2/pt not_active Application Discontinuation
- 2018-12-05 CN CN201880058721.4A patent/CN111065631B/zh active Active
- 2018-12-05 EP EP18886827.7A patent/EP3722286B1/en not_active Not-in-force
- 2018-12-05 UA UAA202003556A patent/UA126005C2/uk unknown
- 2018-12-05 TW TW107143729A patent/TWI717664B/zh not_active IP Right Cessation
- 2018-12-05 CA CA3084201A patent/CA3084201A1/en active Pending
- 2018-12-05 WO PCT/CN2018/119309 patent/WO2019109934A1/zh not_active Ceased
- 2018-12-05 JP JP2020530958A patent/JP2021505596A/ja active Pending
- 2018-12-05 US US16/769,764 patent/US11180530B2/en not_active Expired - Fee Related
-
2020
- 2020-07-02 ZA ZA2020/04055A patent/ZA202004055B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY198899A (en) | 2023-10-02 |
| CN111065631B (zh) | 2021-10-08 |
| AU2018380170A1 (en) | 2020-06-11 |
| EP3722286B1 (en) | 2022-06-22 |
| UA126005C2 (uk) | 2022-07-27 |
| BR112020011191A2 (pt) | 2020-11-17 |
| US20200331963A1 (en) | 2020-10-22 |
| TWI717664B (zh) | 2021-02-01 |
| WO2019109934A1 (zh) | 2019-06-13 |
| ZA202004055B (en) | 2021-08-25 |
| TW201925176A (zh) | 2019-07-01 |
| JP2021505596A (ja) | 2021-02-18 |
| KR20200096588A (ko) | 2020-08-12 |
| EP3722286A1 (en) | 2020-10-14 |
| EP3722286A4 (en) | 2021-08-25 |
| RU2020119583A3 (es) | 2021-12-29 |
| RU2020119583A (ru) | 2021-12-15 |
| US11180530B2 (en) | 2021-11-23 |
| CN111065631A (zh) | 2020-04-24 |
| CA3084201A1 (en) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502227A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| PH12022550156A1 (en) | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| GEAP201914678A (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| GEAP201914680A (en) | New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| GEAP201914679A (en) | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12019501811A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG10201902206QA (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| GEP20207126B (en) | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| MY198899A (en) | Salt of phenylpropionamide derivative and preparation method therefor | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| WO2014125408A3 (en) | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors | |
| MX377202B (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| MY174452A (en) | Substituted piperidines that increase p53 activity and the uses thereof | |
| PH12019500394A1 (en) | Bicyclic nitrogenated heterocyclic compound | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| MX2019010096A (es) | Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa. | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| MY198008A (en) | Crystal of benzofuran derivative free base and preparation method | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| MX2019006939A (es) | Preparacion liquida parenteral que comprende compuesto de carbamato. |